GLYCERYL TRINITRATE (Nitrolingual Pumpspray) (B2)



(Revised: February 2017)

ТҮРЕ:	Nitra	te smooth muscle relaxant and vasodilator [S3]		
PRESENTATION:	Metered dose pumpspray – multiple patient use 400mcg/dose – 200 dose bottle			
ACTIONS:	1. Arterial and venous vasodilation			
	2. Di	ation of collateral coronary vessels		
	-			
USES:	ICP	1. Relieve cardiac pain of ischaemic origin	ΑΡ	
	ICP	2. Relieve pulmonary oedema	ΑΡ	
	ICP	3. Management of autonomic dysreflexia	AP	
DVERSE EFFECTS: 1. Hypotension				
	2. Headache			
	3. Flu	ushing of skin		
	4. Occasionally – reflex bradycardia or tachycardia			
	4.00			
CONTRA-	1 Dc	not administer if systolic BP is <90mmHg		
INDICATIONS:				
	Do not administer if heart rate is <50/min (this does not apply to patients with autonomic dysreflexia)			
	3. Do not administer if patient has taken sildenafil			
		not administer it patient has taken sildenatil		
			ours	
	(<i>V</i>	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h	ours	
	(<i>V.</i> 4. Fo			
	(<i>V.</i> 4. Fo ad	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not		
	(V 4. Fo ad wi	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho		
	(V 4. Fo ad wi pa	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other		
	(V 4. Fo ad wi pa 5. Co	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients		
	(V 4. Fo ad wi pa 5. Cc pr	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients nditions with suspected increased intracranial		
	(V 4. Fo ad wi pa 5. Cc pr	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients nditions with suspected increased intracranial essure (e.g. head trauma, CVA, etc.)		
NOTES:	(V 4. Fo ad wi pa 5. Cc pr	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients nditions with suspected increased intracranial essure (e.g. head trauma, CVA, etc.)		
	(V. 4. Fo ad yi pa 5. Co pr 6. Kn	iagra) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients nditions with suspected increased intracranial essure (e.g. head trauma, CVA, etc.)	se	
 prior to use for t pumpspray by pr 	4. Fo ad wi pa 5. Cc pr 6. Kn	<i>Tagra</i>) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients nditions with suspected increased intracranial essure (e.g. head trauma, CVA, etc.) own hypersensitivity	se	
 prior to use for t pumpspray by pr person/animal 	(V. 4. Fo ad wi pa 5. Co pr 6. Kn he first ressing	<i>iagra</i>) or vardenafil (<i>Levitra</i>) within the past 24 h llowing the last dose of tadalafil (<i>Cialis</i>), do not minister within 4 to 5 days in the elderly and tho th renal impairment, or 3 to 4 days in all other tients nditions with suspected increased intracranial essure (e.g. head trauma, CVA, etc.) own hypersensitivity	se	

continues over

ACT Ambulance Service Clinical Management Guidelines

GLYCERYL TRINITRATE (Nitrolingual Pumpspray) (B2) - cont.

ADMINISTRATION:

- During administration, the patient should be sitting, so that the bottle stays vertical
- Prior to each use, prime the pumpspray as appropriate
- Hold the nozzle head as close to the open mouth as possible, and spray sublingually
- Instruct the patient to close mouth immediately after each dose do not inhale or swallow
- Following each use, wipe down the pumpspray with an alcohol wipe (discard if significantly contaminated). Pumpspray may be used for multiple patients when maintained in this way.

DOSES:

	CHEST PAIN			
ADU	LT:			
ІСР	One metered dose (400mcg), sublingually. Repeat, if necessary, to a maximum of four doses. Five (5) minutes between doses.	АР		
	This dose is suitable for all adult patients, regardless of previous nitrate use.			
PAEI	DIATRIC:			
	Not used.			
	ACUTE CARDIOGENIC PULMONARY OEDEMA			
ADU	LT:			
ICP	One metered dose (400mcg), sublingually. Repeat, after approximately 5 minutes, up to two times, if in severe respiratory distress (total 3 doses).	AP		
	This dose is suitable for all adult patients, regardless of previous nitrate use.			
PAEDIATRIC:				
	Not used.			
AUTONOMIC DYSREFLEXIA				
ADULT:				
ICP	One metered dose (400mcg), sublingually.	ΑΡ		
	If little or no effect – repeat up to two times (total 3 doses), with 5 minutes between doses, monitoring BP.			
PAEI	DIATRIC:			
	Not used.			

ACT Ambulance Service Clinical Management Guidelines

Uncontrolled when printed. The latest version of this document is available on the ACT Ambulance Service internet site.